Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Summary

The purpose of the study was to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF protein levels in treatment naïve wet neovascular Age-related Macular Degeneration (wAMD) patients in a detailed time course.

Timeline

Start

2015-04-08

Primary completion

2017-03-20

Completion

2017-06-08

Outcome

Met primary endpoint

registry analysis (superiority test); Ranibizumab vs Aflibercept and Ranibizumab; p <0.0001; Mean Difference (Final Values) -14.98 (95% CI -19.64 to -10.32) NCT02257632 ↗

Drugs

Indications